[
    [
        {
            "time": "2018-02-02",
            "original_text": "Validea Peter Lynch Strategy Daily Upgrade Report - 2/2/2018",
            "features": {
                "keywords": [
                    "Peter Lynch",
                    "Upgrade",
                    "Strategy"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Validea Peter Lynch Strategy Daily Upgrade Report - 2/2/2018",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 4,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-02-02",
            "original_text": "Validea John Neff Strategy Daily Upgrade Report - 2/2/2018",
            "features": {
                "keywords": [
                    "John Neff",
                    "Upgrade",
                    "Strategy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Validea John Neff Strategy Daily Upgrade Report - 2/2/2018",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 4,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Novartis’s 4Q17 Earnings: Segment-Wise Revenues",
            "features": {
                "keywords": [
                    "Novartis",
                    "Earnings",
                    "Segment-Wise",
                    "Revenues"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novartis’s 4Q17 Earnings: Segment-Wise Revenues",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "AstraZeneca’s 4Q17 Earnings: Analyst Estimates",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Earnings",
                    "Analyst",
                    "Estimates"
                ],
                "sentiment_score": 0.55,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AstraZeneca’s 4Q17 Earnings: Analyst Estimates",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]